Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of the SARS-CoV-2 mRNA chimera vaccine RQ3013 in adults
ChiCTR2200066263Phase 2Not yet recruiting
- Sponsor
- Shandong Provincial Center for Disease Control and Prevention
- Start
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of RQ3013 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Shandong Provincial Center for Disease Control and Prevention. Primary endpoint: Live virus neutralizing antibody titers against the current major endemic SARS-CoV-2 strain. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
RQ3013
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200066263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066263.